Advertisement

Topics

Sciele Pharma, Inc., a Shionogi Company Company Profile

07:06 EDT 23rd September 2017 | BioPortfolio

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


News Articles [2907 Associated News Articles listed on BioPortfolio]

Shionogi Inc Strategic SWOT Analysis Review [Report Updated: 27072017] Prices from USD $125

Shionogi Inc Strategic SWOT Analysis Review provides a comprehensive insight into the company's history, corporate strategy, business structure and operations. The report contains a detailed SWOT ana...

Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients

OSAKA, Japan, July 24, 2017 /PRNewswire/ -- Shionogi & Co., Ltd. (hereafter "Shionogi") has announced that S-033188, a novel cap-dependent endonuclease inhibitor targeting influenza, demonstr...

Shionogi Co., Ltd. Strategy, SWOT and Corporate Finance Report [Report Updated: 02082017] Prices from USD $175

Shionogi Co., Ltd. Strategy, SWOT and Corporate Finance ReportSummaryShionogi Co., Ltd. Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The ...

Shionogi Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Updated: 18052017] Prices from USD $250

SummaryShionogi Inc Shionogi, formerly Sciele Pharma, Inc., is a pharmaceutical company. It undertakes the development and commercialization of pharmaceutical products to address the unmet medical nee...

Shionogi Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 22082017] Prices from USD $250

SummaryShionogi Inc Shionogi, formerly Sciele Pharma, Inc., is a pharmaceutical company. It undertakes the development and commercialization of pharmaceutical products to address the unmet medical nee...

2017 Filing For Shionogi's Novel Flu Drug In Japan On Back Of Strong Phase III Data

Shionogi is on track to file its novel flu treatment S-033188 with regulators in Japan by the end of the...   

Shionogi Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Updated: 03052017] Prices from USD $350

Shionogi Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Shionogi Co., Ltd. Mergers Acquisitions MA, Partnerships Alliances and Investments re...

PeptiDream Inks Peptide Discovery Platform License with Shionogi

PeptiDream said today it has licensed its proprietary Peptide Discovery Platform System (PDPS) technology on a nonexclusive basis to Shionogi & Co. The value of the companies’ Technology Lic...

Drugs and Medications [1514 Associated Drugs and Medications listed on BioPortfolio]

Prenate essential [Sciele Pharma, Inc.]

Prenate Essential™ Rx prenatal vitamin & DHA

Cedax [Sciele Pharma, Inc.]

CEDAX (ceftibuten capsules) and (ceftibuten for oral suspension)

Prenate elite [Shionogi Pharma, Inc.]

PRENATE ELITE Tablets Rx

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 0.5 mg

Fluoride [Libertas Pharma, Inc.]

Fluoride Chewable Tablets 1 mg

PubMed Articles [57 Associated PubMed Articles listed on BioPortfolio]

The moderating role of absorptive capacity and the differential effects of acquisitions and alliances on Big Pharma firms' innovation performance.

In the context of increased pharmaceutical innovation deficits and Big Pharma blockbusters' patent expirations, this paper examines the moderating role of firms' absorptive capacity in external innova...

Delivering advanced therapies: The big pharma approach.

After two decades of focused development and some recent clinical successes, cell and gene therapy (CGT) is emerging as a promising approach to personalized medicines. Genetically engineered cells as ...

Bioanalytical outsourcing: transitioning from Pharma to CRO.

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling.

AI-powered drug discovery captures pharma interest.

Clinical Trials [140 Associated Clinical Trials listed on BioPortfolio]

Epidemiology of Cardiovascular and Non-Cardiovascular Risk In Chicago

To continue the comprehensive research program on the epidemiology of cardiovascular and other major chronic diseases, including cancer and diabetes, in four Chicago population cohorts. T...

Immunogenicity and Safety of Kinrix + MMR With and Without Varicella Vaccine in Healthy Children 4-6 Years

The purpose of the study is to evaluate the immunogenicity and safety of Kinrix when co-administered with varicella (Varivax® [varicella virus vaccine live], Merck and Company) and MMR va...

To Demonstrate the Relative Bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam Tablets In Healthy Adults Volunteers Under Fasting Conditions

To demonstrate the relative bioavailability of Sandoz Inc. and UCB Pharma, Inc (Keppra) 750 mg Levetiracetam tablets in healthy adult volunteers under fasting conditions.

Pharma-Pen (Formerly Innoject) Auto-Injectory TIV

The purpose of this study is to evaluate the safety, effectiveness, and tolerability, of the Pharma-Pen(TM) intramuscular (IM) and subcutaneous (SC) auto-injector systems used by untrained...

A Bioequivalence Study of Cefadroxil From Duricef 1 gm F.C.T (GSK) and Biodroxil 1 gm F.C.T (Novartis Pharma)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Cefadroxil from Duricef 1 gm Film Coated tablets(Smthkline Beecham Egypt,LLC aff...

Companies [2088 Associated Companies listed on BioPortfolio]

Sciele Pharma, Inc.

Shionogi & Co., Ltd. (Head Office: Osaka; President: Isao Teshirogi; hereafter “Shionogi”) today announced that its U.S.-based group company, Sciele Pharma, Inc. (hereaf...

Sciele Pharma, Inc., a Shionogi Company

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3

Shionogi Pharma, Inc.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research ...

Sciele Pharma

Sciele Pharma, Inc. (NASDAQ:SCRX), formerly known as First Horizon Pharmaceutical Corp., is a pharmaceutical company specializing in sales, marketing, and the development of branded prescription produ...

Shionogi & Co., Ltd.

Headquartered in Osaka, Japan, Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients. Shionogi’s Research ...

More Information about "Sciele Pharma, Inc., a Shionogi Company" on BioPortfolio

We have published hundreds of Sciele Pharma, Inc., a Shionogi Company news stories on BioPortfolio along with dozens of Sciele Pharma, Inc., a Shionogi Company Clinical Trials and PubMed Articles about Sciele Pharma, Inc., a Shionogi Company for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sciele Pharma, Inc., a Shionogi Company Companies in our database. You can also find out about relevant Sciele Pharma, Inc., a Shionogi Company Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record